United States: New Jersey Accutane Plaintiff Verdict Vacated – Appellate Division Strongly Criticizes Evidentiary Rulings

Last Updated: July 26 2016
Article by Michelle Yeary

If you read the decision in Rossitto v. Hoffman-LaRoche Inc., 2016 N.J. Super. Unpub. LEXIS 1714 (N.J. App. Div. Jul 22, 2016), we think you'll agree with our calling it "strong" criticism of two trial rulings that the appellate court firmly believed led to undue prejudice of the defendant. The $18 million verdict awarded to two of four plaintiffs in a joint trial was vacated and the case is being remanded for a new trial. This is not the first Accutane plaintiff's verdict to be vacated by New Jersey's appellate division, but rather another notch in the demise of this litigation which has seen a turn in favor of defendant since coming under new management. Indeed, a quick search of the DDL blog for Accutane will show how the tide has turned.

The Accutane litigation is primarily comprised of claims alleging that the manufacturer failed to adequately warn about the risk of inflammatory bowel disease ("IBD"). Therefore, the drug's label takes center stage. Here, the plaintiffs both used the drug with its 1984 label that included a warning that "Accutane has been temporally associated with IBD." Id. at *8. In May 2000, after plaintiffs had stopped using Accutane, the label was revised to remove the word "temporally" and to add information about persistent IBD symptoms. Id. at *18.

Although only one of the plaintiffs was a New Jersey resident, the parties agreed that New Jersey law would apply to both. Id. at *34. So, New Jersey's "super-presumption" applies – that is if the warning given has been approved by the FDA, there is a rebuttable presumption of adequacy. Id. at *37. Called a "super-presumption" because it is "virtually dispositive" on failure to warn, it can be overcome with evidence of intentional concealment of a known risk or "substantial evidence of economically-driven manipulation of the post-market regulatory process." Id. at *37-38. Plaintiffs got to trial in these cases because the New Jersey courts have found that as to the 1984 label plaintiffs have put forth enough evidence from which a reasonable jury could conclude they had rebutted the presumption. Id. at *55-56 (citing prior Accutane decisions addressing this issue). But it's a strong presumption so we decided to take the time to remind you about it.

With the 1984 label being the operative label, the question on appeal is whether the trial court erred in allowing into evidence the 2000 label change which defendant argued should have been excluded as a subsequent remedial measure. The answer was a resounding yes; finding the trial court's ruling "ill-advised" and an error "of such magnitude . . . to warrant relief." Id. at *47.

New Jersey Rule of Evidence 407, similar to the federal rule, provides that "[e]vidence of remedial measures taken after an event is not admissible to prove that the event was caused by negligence or culpable conduct." This rule is primarily based on the strong public policy encouraging remedial measures and for that reason if the action taken was mandated by the government as opposed to undertaken voluntarily, it is not barred by Rule 407. In addition, subsequent remedial measures can be admitted for "other purposes" such as impeachment, if not unduly prejudicial. Id. at *39-40.

In Rossitto, it appears the court first excluded the 2000 label change under Rule 407 as a non-mandated subsequent remedial measure. Id. at *41. During trial testimony by one of the manufacturer's company witnesses on the strength of the 1984 label, the court "altered its course" and granted plaintiffs' request to admit the 2000 label for purposes of impeaching the witness. Id. at *42. Ruling on defendant's post-trial motion for JNOV, the trial court also concluded that the label change was not voluntary because the revision was "suggested" by the FDA and defendant "agreed." Id. at *40-41, 42.

The appellate division found this to be a "serious" error. Id. at *42:

The court originally – and correctly – recognized before this trial began the substantial prejudice to [defendant] in allowing the subsequent post-ingestion labeling change to be considered by the jury. It should not have strayed from that correct determination.

Id. at *43.

As for whether the label change was FDA-mandated, the court noted that the FDA did not have authority to "mandate" such a change until 2007. Nor was the court persuaded that proposing a change made the defendant's decision to adopt the change involuntary. Id. So, the label change was a subsequent remedial measure within the scope of Rule 407.

That leaves whether the 2000 label was properly admitted for purposes of impeachment. Plaintiffs argued and the trial court agreed that the defendant opened the door when its witness testified to the sufficiency of the 1984 label. By that reasoning, the exception would swallow the rule. "[S]uch a retrospective defensive posture is a natural aspect of a classic Rule 407 factual paradigm, in which defendants and their witnesses are tasked with justifying the sufficiency of past conduct or the benign quality of past conditions that preceded a subsequent remedial change. Id. at *44.

Further, any impeachment value was substantially outweighed by the "strong prejudice" to defendant. "[T]he 2000 label change could easily have been viewed by the jurors as 'smoking gun' evidence, signifying that the Accutane label that had preceded the 2000 version was deficient." Id. at *43-44.

Moreover, the limited admission for purposes of impeachment apparently flew out the window at the time of plaintiffs' summation during which plaintiffs' counsel spent "substantial" time focused on defendant's conduct post-plaintiffs' ingestion of the drug including the "stronger" 2000 label. The appellate court found that "the 2000 label change was used within plaintiffs' advocacy for its substantive evidential power." Id. at *46. There was no legitimate basis for admission of the 2000 label change and the "improvident" decision to allow it was only compounded by allowing plaintiffs to use it substantively.

The label change wasn't the only reversible error. The trial court also limited the number of expert witnesses the defendant could present on particular subjects. The appellate division addressed this issue in another case that came after the trial in Rossitto, McLean v. Liberty Health System, 430 N.J. Super. 156 (App. Div. 2013). The upshot is that in complex cases like medical malpractice and pharmaceutical products liability, trial courts should not limit experts to one per side per issue. There is a difference between "duplicative" evidence and "needless . . . cumulative evidence." Rossitto, 2016 N.J. Super Unpub. LEXIS 1714 at *49. In this case, the court precluded defendant from offering testimony from its four experts on issues related to general causation while plaintiffs were permitted to elicit general cause testimony from two experts. Id. at *50. The inability to put in its expert case the way it wanted was certainly prejudicial to defendant and the appellate court agreed that the defense should have been given "freer rein" to overlap key causation opinions. Id. at *51.

The appellate decision goes on to address some additional arguments raised by the defendants that the court did not believe gave rise to reversible error but most are fairly case specific, so we won't get into them here.

Congratulations yet again to Covington and Burling, Paul Schmidt and Mike Imbroscio, for their continued success in winning reversal of adverse Accutane verdicts in New Jersey, and for sending this latest one to us.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.